Importantly, we have shown significant response to the FAK inhibitor PF-562,271 alone, or the combination of BMS754807 and dasatinib in patient ex vivo human HNSCC tumors suggesting that potential exists for targeting FAK, IGF1R, and Src in HNSCC. This evidence concerns the gene PTK2 and head and neck squamous cell carcinoma.